Skip to main content
. 2017 Jan 19;8(9):14655–14665. doi: 10.18632/oncotarget.14738

Figure 1. miR-29b was up-regulated upon treatment with cisplatin.

Figure 1

(A) Heat-map showing the expression profiles significantly differentially expressed in HeLa and Caski cells upon treatment with miR-29b. (B) The expression of six miRNAs in HeLa and Caski cells upon treatment with cisplatin was detected by quantitative RT-PCR. Data are shown as log10 of relative ratio change of the miRNAs relative to GAPDH; (C) Statistical analysis of relative mean level of miR-29b expression in 19 paired of cervical cancer tissues before and after chemotherapy with cisplatin; The expression of miR-29b was significantly increased upon treatment with cisplatin. (D) Statistical analysis of relative mean level of miR-29b expression in cervical cancer, HSIL tissues and normal tissues. Statistical analysis of relative mean level of miR-29b expression in a cohort of 22 cases of cervical cancers, 10 cases of high-grade squamous intraepithelial lesions (HSIL) and 5 cases of normal cervical tissues. The expression of miR-29b was suppressed in CC and HSIL tissues compared to normal tissues. (E) Statistical analysis of relative mean level of miR-29b expression in CC patients with different clinical stages. The expression of miR-29b was suppressed in later stages (stages IB compared with stages IIA and IIB). The data are representative of at least three independent experiments. Error bars represent s.e.m. **P < 0.01.